Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zobair Younossi

Showing results (1-10 of 128) with videos related to

Pageof 13
Sort By:
Gastroenterology & Hepatology|August 9, 2019
Emerging Research on MGL-3196 for the Treatment of Nonalcoholic SteatohepatitisZobair Younossi
Clinical Liver Disease|May 2, 2019
What is the ethical responsibility of a provider when prescribing the new direct-acting antiviral agents to patients with hepatitis C infection?Zobair Younossi
Gastroenterology|March 17, 2016
Contribution of Alcoholic and Nonalcoholic Fatty Liver Disease to the Burden of Liver-Related Morbidity and MortalityZobair Younossi, Linda Henry
Journal of Hepatology|January 21, 2015
Can NASH lipidome provide insight into the pathogenesis of obesity-related non-alcoholic fatty liver disease?Aybike Birerdinc, Zobair Younossi
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 3, 2014
The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis CZobair Younossi, Linda Henry
Hepatology (Baltimore, Md.)|September 12, 2020
Integrating Patient-Reported Outcomes Within Routine Hepatology Care: A Prompt to ActionManisha Verma, Zobair Younossi
Alimentary Pharmacology & Therapeutics|December 24, 2022
Editorial: changes of health-related quality of life associated with hepatic disease severity and its improvement after treatment in NAFLD-authors' replyYusuf Yilmaz, Zobair Younossi
Alimentary Pharmacology & Therapeutics|May 27, 2023
Editorial: optimal combination of non-invasive tests to determine significant fibrosis in non-alcoholic fatty liver disease-authors' replyMaria Stepanova, Zobair Younossi
Cleveland Clinic Journal of Medicine|October 16, 2003
Treatment options for nonresponders and relapsers to initial therapy for hepatitis CMarten Duncan, Zobair Younossi
Hepatology (Baltimore, Md.)|October 24, 2006
Diabetic hepatosclerosis: a novel entity or a rare form of nonalcoholic fatty liver disease?Michael Mendoza, Zobair Younossi
Pageof 13

Showing results (1-10 of 128) with videos related to

Sort By:
Pageof 13
Gastroenterology & Hepatology|August 9, 2019
Emerging Research on MGL-3196 for the Treatment of Nonalcoholic SteatohepatitisZobair Younossi
Clinical Liver Disease|May 2, 2019
What is the ethical responsibility of a provider when prescribing the new direct-acting antiviral agents to patients with hepatitis C infection?Zobair Younossi
Gastroenterology|March 17, 2016
Contribution of Alcoholic and Nonalcoholic Fatty Liver Disease to the Burden of Liver-Related Morbidity and MortalityZobair Younossi, Linda Henry
Journal of Hepatology|January 21, 2015
Can NASH lipidome provide insight into the pathogenesis of obesity-related non-alcoholic fatty liver disease?Aybike Birerdinc, Zobair Younossi
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 3, 2014
The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis CZobair Younossi, Linda Henry
Hepatology (Baltimore, Md.)|September 12, 2020
Integrating Patient-Reported Outcomes Within Routine Hepatology Care: A Prompt to ActionManisha Verma, Zobair Younossi
Alimentary Pharmacology & Therapeutics|December 24, 2022
Editorial: changes of health-related quality of life associated with hepatic disease severity and its improvement after treatment in NAFLD-authors' replyYusuf Yilmaz, Zobair Younossi
Alimentary Pharmacology & Therapeutics|May 27, 2023
Editorial: optimal combination of non-invasive tests to determine significant fibrosis in non-alcoholic fatty liver disease-authors' replyMaria Stepanova, Zobair Younossi
Cleveland Clinic Journal of Medicine|October 16, 2003
Treatment options for nonresponders and relapsers to initial therapy for hepatitis CMarten Duncan, Zobair Younossi
Hepatology (Baltimore, Md.)|October 24, 2006
Diabetic hepatosclerosis: a novel entity or a rare form of nonalcoholic fatty liver disease?Michael Mendoza, Zobair Younossi
Pageof 13